In particular, anlotinib (AL3818) is a multi-TKI targeting VEGFR1-3, FGFR1-4, PDGFRα/β, and c-Kit and Ret was approved as a third-line or beyond therapy for stage IV NSCLC. Here, FGFR1 is linked to non-small cell lung carcinoma.